Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, unveils new features for its Epione® robotic platform at the 2026 annual congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
The updated platform features new AI capabilities and compatibility with one of the latest-generation angiography systems from GE HealthCare enabling greater mobility.
Epione is an AI- and robotic-assisted percutaneous ablation platform that integrates every step of the procedure — planning, targeting, delivery, and confirmation.
Epione is used to treat abdominal, chest, and musculoskeletal tumors and lesions (1), and is also available for bone consolidation procedures (2).
At CIRSE, Precision IO introduces two new capabilities:
• Smart Seg AI, a software tool powered by deep-learning algorithms trained on thousands of CT scan images optimizing the segmentation of tumors in the liver
• The compatibility with the Allia™ Moveo INTERACT Touch panel, developed in collaboration with GE HealthCare, an industry leader, to offer physicians a seamless experience. Combining high-quality 3D imaging, treatment-planning capabilities, and robotic needle guidance, the integrated solution supports accurate target visualization and precise needle placement for complex percutaneous procedures.
Our collaboration with GE HealthCare reflects a shared commitment to innovation and to advancing the future of image-guided interventions. We are proud that the flexibility of the Epione® platform and our team’s expertise have enabled a seamless integration with the Allia™ Moveo (3) INTERACT Touch panel, creating a more streamlined workflow that allows physicians to stay focused on what matters most: the patient.
Kurt Azarbarzin, CEO of Precision IO Group, parent company of Quantum Surgical.
Precision IO Group is a private interventional oncology company advancing the technologies physicians use to perform minimally invasive treatment of solid tumors. The company’s two operating subsidiaries — NeuWave Medical and Quantum Surgical — develop and commercialize microwave ablation systems and the Epione® robotic ablation platform, respectively.
Precision IO Group was formed in 2026 following the acquisition of NeuWave Medical from Johnson & Johnson MedTech, is backed by Ally Bridge Group, and employs more than 275 people worldwide.
The company’s mission is to make precision cancer care universally available, empowering physicians to treat more challenging lesions with consistent, evidence-backed solutions.
By integrating robotics, artificial intelligence, and remote-enabled interventions, Precision IO Group aims to advance the standard of care in tumor ablation.
